3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
17
Breast
4
Genitourinary
3
Thoracic
2
Sarcoma
2
Gastrointestinal
2
Dermatologic
2
Head & Neck
1
CNS
1
Conditions
Thyroid Neoplasms
5
Breast Neoplasms
3
Thyroid Carcinoma, Anaplastic
2
Squamous Cell Carcinoma of Head and Neck
2
Sarcoma
2
Head and Neck Neoplasms
2
Thyroid Cancer, Papillary
1
Salivary Gland Neoplasms
1
Recurrent Lymphoepithelioma of the Nasopharynx
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Melanoma
1
Lung Neoplasms
1
Liver Neoplasms
1
Kidney Neoplasms
1
Gastrointestinal Neoplasms
1
Endometrial Neoplasms
1
Colonic Neoplasms
1
Cholangiocarcinoma
1
Central Nervous System Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Medullary
1
Adenocarcinoma, Follicular
1
Interventions
pembrolizumab
28
Nivolumab
13
Carboplatin
9
fludarabine
7
Paclitaxel
7
Gemcitabine
7
Docetaxel
7
Cyclophosphamide
7
Cisplatin
7
Trastuzumab
5
palbociclib
4
cemiplimab
4
avelumab
4
atezolizumab
4
Ipilimumab
4
Fluorouracil
4
Filgrastim
4
Drug Therapy
4
Cetuximab
4
fludarabine phosphate
3
epacadostat
3
durvalumab
3
Taxes
3
Oxaliplatin
3
Fulvestrant
3
zimberelimab
2
ulixertinib
2
trametinib
2
tisotumab vedotin
2
spartalizumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Ovarian Neoplasms
×
pazopanib
×
Head & Neck
×
Clear all
NCT05949424
2023-11-29
OPTI-DOSE
University Medical Center Groningen
Phase 4
Unknown
30 enrolled